- €155.90bn
- €202.32bn
- $62.58bn
Bristol Myers to build $2.3 billion manufacturing site in Houston
Street View: Growth drugs lift Pfizer outlook, but execution remains key
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco
U.S. STOCKS ON THE MOVE-Expeditors International, Waters, Wayfair
Brief: Pfizer Says Net Cost Savings From Now Expected To Reach $6.7 Billion Through 2029
Pfizer Inc reports results for the quarter ended June 30 - Earnings Summary
Advisory: Stray alert from NYSE tagged to multiple companies withdrawn
U.S. STOCKS ON THE MOVE-Zebra Technologies, Pfizer, Cummins
Pfizer edges up after better-than-expected quarterly results
Pfizer Q2 results beat; raises 2026 revenue outlook
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts (updated)
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
AstraZeneca US M&A idea would ail more than cure
Eli Lilly is pharma’s latest victim of success
Eli Lilly is pharma’s latest victim of success
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results (updated)
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Brief: Bristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results